---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-001787"
form_type: "8-K"
ticker: "RNXT"
cik: "0001574094"
company_name: "RenovoRx, Inc."
filed_at: "2023-01-18T23:59:59+00:00"
generated_at: "2026-06-20T14:02:05.809872+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# RenovoRx PK substudy shows >50% reduction in systemic drug exposure with RenovoTAMP

## Summary
- In 13 LAPC patients, intra-arterial gemcitabine via RenovoTAMP reduced systemic drug exposure by >50% vs IV.
- Data presented at ASCO GI Symposium January 19-21, 2023, along with three additional abstracts.
- TIGeR-PaC trial: 47 of 114 target patients randomized; 25 deaths reported to date.
- Additional abstracts cover mesenteric venous thrombosis prevalence and SBRT vs IMRT tolerability.

## SEC filing metadata
- accession: 0001493152-23-001787
- form_type: 8-K
- ticker: RNXT
- cik: 0001574094
- company_name: RenovoRx, Inc.
- filed_at: 2023-01-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1574094/000149315223001787/0001493152-23-001787-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1574094/000149315223001787/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-001787
- JSON: https://secwatch.observer/filing/0001493152-23-001787.json
- Plain text: https://secwatch.observer/filing/0001493152-23-001787.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.